ZENAS BIOPHARMA INC (ZBIO)
Health Care · biotechnology · NASDAQ
Clinical-stage immunology company developing obexelimab, a novel bifunctional monoclonal antibody targeting B cells for the treatment of autoimmune diseases.
What ZENAS BIOPHARMA INC does
Zenas Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative immunology-based therapies for autoimmune diseases. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit B cell activity by targeting CD19 and FcγRIIb without depleting the cells. The company's pipeline targets multiple indications, including IgG4-related disease (IgG4-RD), relapsing multiple sclerosis (RMS), and systemic lupus erythematosus (SLE).
Themes: immunology and inflammation, autoimmune disease therapeutics, B cell therapy, monoclonal antibodies
Fundamentals
- Price$32.29 as of 2026-08-21 close
- Market cap$2.1B as of 2026-08-21
- 1-year return+90.7% 2025-08-21 close $16.93 → 2026-08-21 close $32.29
- P/En/a negative earnings
- Net margin-3777.4% as of 2026-08-24
- ROE-167.7% as of 2026-08-24
- Debt / equity1.04 as of 2026-08-24
- Revenue growth (YoY)+100.0% FY2025 vs FY2024, SEC XBRL
- Revenue CAGR (3y)-55.3% SEC XBRL
- Beta0.70 as of 2026-08-24
- Last reported earnings2026-08-13 SEC EDGAR Form 8-K (Item 2.02)
How ZBIO compares in its sector
- net profit marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- operating marginbottom 10% 504 covered Health Care peers, as of 2026-08-24
- return on equitybottom 25% 576 covered Health Care peers, as of 2026-08-24
- 3-year revenue CAGRbottom 10% 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)bottom 25% 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
ZBIO is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
72.8 #1 of 1,704 scored · #1 of 240 in Health Care
Setup 93rd: no fresh 20-day breakout up or down; catalysts 76th: analysts have raised their average price target by 8.0% since the prior reading; weakest is momentum 53rd: MACD momentum is negative.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How ZENAS BIOPHARMA INC looks technically
ZENAS BIOPHARMA INC (ZBIO) is trading 22.4% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 8 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 20 trading days ago. It is 27.6% below its highest point of the past year. Day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move.
Trend
9
| Distance from the 200-day | it is trading 22.4% above its 200-day average, the long-term trend line — a longer-term uptrend | +22.4% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $28.06 | $28.06 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $26.37 | $26.37 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 8 calendar days ago — the swings before that are what the structure reading is measured on | 8 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 27.81. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 8 trading days ago — a "golden cross", a bullish long-term signal | 8 sessions |
| Above the 200-day after a dip | it recently dipped to its 200-day average (the long-term trend line) and has since climbed back above it — now about 22.4% above | +22.4% |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 28, with buyers in control | 27.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 58, neither overbought (above 70) nor oversold (below 30) | 58.5 |
|---|---|---|
| Position in its 14-day range | it is trading near the top of its 14-day range ($27.81 to $33.08) — its "stochastic" reading is 85 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 85.0 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in negative territory (momentum leaning bearish) | 18 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $44.60 | $44.60 |
|---|---|---|
| From the 52-week high | it is 27.6% below its 52-week high (its highest price of the past year) | -27.6% |
| Above the 52-week low | it is 139.2% above its 52-week low (its lowest price of the past year) | +139.2% |
| Below the 52-week high | it is 27.6% below its highest point of the past year | 27.6% |
| Since a 20-day breakout | it made a new 20-day high about 20 trading days ago | 20 sessions |
| Since a 55-day breakout | it made a new 55-day high about 20 trading days ago | 20 sessions |
| All-time high | its highest closing price on record is $50.95 (set on 2016-02-09) | $50.95 |
| Given back of the 52-week move | over the past year its closes ranged ($15.20 to $43.17), and it has recovered a bit over half of its fall from last year’s high — 61% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $32.49 to $33.38. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. Worth noting that the whole move happened in 13 days, so it is a narrow thing to be measuring a retracement against. | 61.1% |
| From the all-time high | it is 36.6% below its all-time high | -36.6% |
| Nearest price level | it is trading 6.0% below a resistance level at $34.21 — a price it turned at three times since 2025-10-27, most recently on 2026-07-21. Since 2024-09-13 it has 12 such levels below the current price and 1 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +6.0% |
| All-time low | its lowest closing price on record is $5.83 (set on 2025-01-28) | $5.83 |
| Above the all-time low | it is 453.9% above its all-time low | +453.9% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are unusually narrow versus its own recent history — a "Bollinger squeeze" (in the tightest 2% of the past ~6 months), which often precedes a bigger move | 2nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $1.94 between its high and its low — about 6.0% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $1.94 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $29.70 and $33.39 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $29.70 – $31.55 – $33.39 |
| Typical daily range (% of price) | its price moves about 6.0% in a typical session — more volatile than most companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 6.0% |
| Stretch from the 200-day average | it is trading 3.1 daily ranges above its 200-day average price (22.4% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 3.1 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.02× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 8.0% since the prior reading | +8.1% |
|---|---|---|
| Change in the consensus rating | not available for this company yet | n/a |
Candlestick patterns
2
| Since a hammer | 4 sessions ago, after a stretch of decline, it sold off hard during the session and then closed back near its high — a "hammer", the long lower wick showing the drop was bought back before the close | 4 sessions ago |
|---|---|---|
| Since a bullish engulfing | 8 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.7% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and traded back through that level before the close | +0.7% |
|---|---|---|
| Open gap | it gapped 2.1% above the previous close 43 sessions ago and has not traded back through the level it left behind at 19.78 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.1% |
| Gap filled | a 2.8% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it has closed higher 2 sessions in a row, a +3.33% move over the run — an unbroken run of up days, which describes what has already happened and says nothing about the next session | 2 sessions up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 2.5 percentage points (the stock lost 0.2% while the market gained 2.3%) | -2.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 59.7 percentage points (the stock gained 62.8% while the market gained 3.1%) | +59.7% |
| vs market, 6 months | over the past 6 months this stock beat the market by 13.7 percentage points (the stock gained 24.8% while the market gained 11.1%) | +13.7% |
| vs market, 12 months | over the past 12 months this stock beat the market by 70.2 percentage points (the stock gained 90.7% while the market gained 20.5%) | +70.3% |
Signal agreement
2
| Bullish technical signals | 5 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 5 of 9 |
|---|---|---|
| Bearish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bearish state: MACD momentum is negative, near the top of its 14-day range (overbought) — these describe past price behaviour, not a forecast | 2 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 26% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 7.6% of the share price. | +25.8% |
|---|
Volume-weighted price
1
| Vs this year’s average price paid | the price is 40% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $23.00 — a volume-weighted average of daily closes over 154 sessions, not a true tick-by-tick VWAP. | +40.4% |
|---|
Price levels it has turned at before
ZBIO last closed at $32.29 on 2026-08-21. Since 2024-09-13 it has turned at 12 prices below its last close and 1 above; the 3 nearest below and the nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $34.21 | Resistance | 6.0% above the last close | turned there three times · 2025-10-27 to 2026-07-21 |
| $29.76 | Support | 7.8% below the last close | turned there three times · 2025-10-10 to 2026-07-09 |
| $27.80 | Support | 13.9% below the last close | turned there twice · 2026-02-25 to 2026-08-13 |
| $22.67 | Support | 29.8% below the last close | turned there three times · 2026-01-14 to 2026-04-06 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $27.81.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $45.45 and $56.35 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $27.81.
This reading has stood for 2 trading days, since 2026-08-20.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · Recent golden cross (50-day crossed above 200-day) · Tested and reclaimed 200-day support · Pulled back from the 12-month high · in a Bollinger Band volatility squeeze · in a strong, established uptrend (ADX) | Learn: moving average · golden cross · adx · rsi · breakout · fifty two week high low · bollinger bands
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.25 mean, 1=Strong Buy…5=Strong Sell) — 8 analysts
- Mean price target$47.00 range $32.00 – $59.00; median $45.00
Analyst estimates, as of 2026-08-18. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ZBIO
- Consensus EPS estimate-$1.27 next reporting period, as of 2026-08-18
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Clinical trial failure or negative results could materially harm business prospects and stock price.","Dependence on the success of lead candidate obexelimab.","Substantial losses and requirement for additional financing to fund operations."]
What changed in the latest 10-Q
AI-assisted comparison of ZBIO's 10-Q filed 2026-05-13 against the prior one filed 2025-11-12.
Management's Discussion & Analysis (MD&A)
- Added:
- Reference to Form 10-K filed on March 16, 2026 (newer filing) vs. March 11, 2025 (older filing)
- January 2026 positive Phase 3 results for obexelimab in IgG4-RD with 56% risk reduction in flare (HR 0.44, p=0.0005)
- Plan to submit BLA to FDA for IgG4-RD in Q2 2026
- Plan to submit Marketing Authorization Application to EMA in H2 2026
- February 2026 24-week data from MoonStone trial showing maintained reductions in GdE T1 lesions (0.87 baseline, 0.08 at week 12, 0.04 at week 24, 95% reduction)
- April 2026 completion of SunStone trial enrollment
- March 2026 initiation of Phase 3 trial for orelabrutinib in naSPMS (non-active secondary progressive MS)
- Reference to InnoCare License Agreement dated October 2025 (vs. October 7, 2025 in older)
- Removed:
- Reference to INDIGO trial name in context of IgG4-RD trial
- Statement that INDIGO trial completed target enrollment in Q4 2024
- Statement expecting INDIGO topline results around year-end 2025
- Statement that positive INDIGO results would lead to BLA filing in H1 2026
- Statement of expectation to report SunStone results in mid-2026
- Statement planning to initiate second SPMS Phase 3 trial in Q1 2026
- Reference to 'SPMS' designation without qualifier 'non-active'
- Statement that ZB021 achieved comparable activity in vivo in rat CIA model
- Conditional language about submitting IND for ZB021 and initiating Phase 1 in 2026
- Statement that ZB022 is in IND-enabling studies with conditional phase 1 timeline
- Reworded:
- Changed from 'IgG4-RD through an ongoing registration-directed Phase 3 trial (the "INDIGO" trial)' to describing completed Phase 3 trial with reported results
- Changed from 'RMS through an ongoing Phase 2' to clarifying trial completion status and reporting timing
- Changed from 'expects to report 24-week data...in the first quarter of 2026' to past tense 'reported the 24-week data...in February 2026'
- Changed from 'expects to report topline results from the SunStone trial in mid-2026' to 'expect to report topline results...in the fourth quarter of 2026'
- Changed from 'we plan to initiate a second' SPMS trial to 'we initiated a second' SPMS trial in March 2026
- Changed terminology from 'Secondary Progressive Multiple Sclerosis (SPMS)' to 'non-active secondary progressive multiple sclerosis (naSPMS)'
- Updated description of primary endpoint from 'cCDP' to '24-week CDP' for SPMS trial
- Changed from reference to 'October 7, 2025' date to 'October 2025' for InnoCare License Agreement
- Notes:
- Older filing contains incomplete text that cuts off mid-sentence regarding the InnoCare License Agreement
- Comparison is between Q1 2026 10-Q (newer, filed May 13, 2026) and Q3 2025 10-Q (older, filed November 12, 2025), representing different reporting periods and temporal perspectives
Risk Factors
- Added:
- New section 'Risks Related to Government Regulation' added in 2026-05-13 filing discussing political, trade, and regulatory developments between U.S. and China
- Reference to tariffs on patented pharmaceutical products imposed in April 2026
- Reference to tariffs imposed in March and April 2025 by the U.S. on imports from foreign countries
- Discussion of WuXi Biologics as current sole CMO for obexelimab and InnoCare as collaboration partner for orelabrutinib supply
- Reference to new CMOs selected in the U.S. for obexelimab
- New section 'Risks Related to our Indebtedness' added in 2026-05-13 filing
- Discussion of Loan Agreement maturing in 2031 and Convertible Notes obligations
- Reference to Royalty Purchase Agreement secured obligations
- Discussion of fundamental change repurchase provisions for Convertible Notes
- Removed:
- Section 'Risks Related to Our Financial Position and Need for Capital' removed from 2026-05-13 filing (was in 2025-11-12 filing)
- Specific net loss figures ($51.5 million for Q3 2025, $38.6 million for Q3 2024, $137.3 million for nine months 2025, $104.4 million for nine months 2024) removed
- Accumulated deficit figure of $524.7 million as of September 30, 2025 removed
- Cash position figure of $301.6 million in cash, cash equivalents and investments as of September 30, 2025 removed
- Going concern language and substantial doubt statement removed
- Detailed discussion of anticipated expense increases across multiple operational areas removed
- Reworded:
- Opening paragraph expanded to reference 'Annual Report on Form 10-K for the year ended December 31, 2025' in newer filing versus generic reference to risks in older filing
- Reference to 'risks described below' changed to 'risks uncertainties and other factors, contained in the risk factors disclosed' in newer filing
- Order and organization of risk factors restructured between filings
- Notes:
- The older filing text appears truncated at the end; comparison limited to available content
- The newer filing text also appears truncated mid-sentence; full scope of additions/removals may be incomplete
- These represent Q3 2025 filing versus Q2 2026 filing; different reporting periods complicate comparison
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days.
- Last 180 days4 buys ($2M) · 0 sells — 2 buying insiders
Most recent open-market transaction: 2026-05-18. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ZBIO's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
4 institutional 13F filers reported holding ZBIO as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 4
- Reported shares held 12,718,141
- Reported value $248,639,658
reported quarterly holdings change (2025-12-31 → 2026-03-31): 0 new, 4 increased, 0 decreased, 0 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
ZBIO had 11,753,566 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
ZBIO had 18.0% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 13.83 days to cover at the same settlement.
- Reported short interest (shares) 11,753,566
- Short interest (% of shares outstanding) 18.0%
- Prior settlement (shares) 12,169,907
- Reported change -3.42%
- Days to cover (reported) 13.83
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
- Roche (RHHBY)
- Novartis (NVS)
- Sanofi (SNY)
- Amgen (AMGN)
- Bristol Myers Squibb (BMY)
- Biogen (BIIB)
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ZBIO vs…
ZENAS BIOPHARMA INC is found in…
Frequently asked questions
What does ZENAS BIOPHARMA INC (ZBIO) do?
Zenas Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing transformative immunology-based therapies for autoimmune diseases. Its lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to inhibit B cell activity by targeting CD19 and FcγRIIb without depleting the cells.
What sector is ZENAS BIOPHARMA INC (ZBIO) in?
ZENAS BIOPHARMA INC (ZBIO) is classified in the Health Care sector. Its industry is biotechnology. It trades on NASDAQ.
Who are ZENAS BIOPHARMA INC's (ZBIO) competitors?
Notable peers of ZENAS BIOPHARMA INC (ZBIO) include Roche, Novartis, Sanofi, Amgen and Bristol Myers Squibb. This peer set is informational only — not financial advice.
Is ZENAS BIOPHARMA INC (ZBIO) overbought or oversold right now?
ZENAS BIOPHARMA INC (ZBIO) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 58, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ZBIO come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.